Wantai Biotech (603392.SH): Has repurchased a total of 539,500 shares

Gelonghui, May 6, 丨 Wantai Biotech (603392.SH) announced that as of April 30, 2024, the company had repurchased 539,500 shares through centralized bidding transactions, accounting for 0.0425% of the company's total share capital. The highest price of the repurchase transaction was 70.19 yuan/share, the lowest price was 45.55 yuan/share, and the total amount of capital paid was RMB 28,651,117.96 (not including transaction fees such as transaction fees).

Gelonghui FinanceMay 6 16:41

Do Its Financials Have Any Role To Play In Driving Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.'s (SHSE:603392) Stock Up Recently?

Most readers would already be aware that Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) stock increased significantly by 26% over the past three months. We wonder if and what role the

Simply Wall StMay 1 12:59

Wantai Biotech (603392): 2024Q1 performance is under pressure, pending the launch of the nine-valent HPV vaccine

Incident: Wantai Biotech released its 2024 quarterly report. In the first quarter of 2024, the company achieved operating income of 753 million yuan, a year-on-year decrease of 73.93%; net profit to mother was 126 million yuan, a year-on-year decrease of 89.90%;

國投證券Apr 30 00:00

Express News | Wantai Biotech: Net profit from mother in the first quarter was 126 million yuan, a year-on-year decrease of 89.9%

BreakingsApr 25 18:02

Express News | Wantai Biotech successfully signed a regional strategic cooperation agreement with China Resources Medical Technology (Hebei) Co., Ltd.

BreakingsApr 23 15:00

Wantai Biological's Phase 3 Trials for Nine-Valent HPV Vaccine Yields Performed 'As Expected'

Wantai Biological Pharmacy Enterprise's (SHA:603392) phase 3 trials for its nine-valent human papillomavirus vaccine yielded expected results, according to a Thursday filing with the Shanghai bourse.

MT NewswiresApr 12 17:48